Blog
RSS FeedPosted by Michael Wonder on 13 Nov 2023
Informing real-time decisions with post-market drug evidence
10 November 2023 - It’s been one year since CADTH launched the Post-Market Drug Evaluation (PMDE) Program to provide decision-makers with ...
Posted by Michael Wonder on 13 Jun 2023
Pilot expert committee to support decision-making across the drug life cycle
8 June 2023 - CADTH, Canada’s drug and health technology agency, announces the creation and inaugural membership of a new ...
Posted by Michael Wonder on 12 Oct 2021
Outdated criteria for drug plan reimbursement obstruct evidence based care
12 October 2021 - An important flaw in the funding approach used by Canada’s public drug plans is highlighted by the ...
Posted by Michael Wonder on 29 Apr 2021
Integration of ethical considerations into HTA reports: an analysis of integration levels using a systematic review
26 April 2021 - The objective was to describe the type and level of ethical integration in published health technology assessment ...
Posted by Michael Wonder on 24 Jan 2021
Creating a patient and community advisory committee at the Canadian Agency for Drugs and Technologies in Health
22 January 2021 - In recognition of patients’ roles using, and contributing to, a publicly funded health system, the Canadian Agency ...
Posted by Michael Wonder on 10 Aug 2020
Can multi-criteria decision analysis be implemented into real world drug decision-making processes? A Canadian provincial experience
7 August 2020 - This paper describes the implementation of multi-criteria decision analysis into a Canadian public drug reimbursement decision-making process, ...
Posted by Michael Wonder on 18 Nov 2019
Picturing ELSI+: a visual representation of ethical, legal, and social issues, and patient experiences in health technology assessment in Canada
15 November 2019 - Consideration of ethical, legal, and social issues plus patient values (ELSI+) in health technology assessment is challenging ...
Posted by Michael Wonder on 22 Jul 2019
Should national pharmacare apply a value based insurance design?
22 July 2019 - The final report of the Advisory Council on the Implementation of National Pharmacare, published in June 2019, ...
Posted by Michael Wonder on 10 Jul 2019
New committee brings diverse patient, family, and caregiver voices to CADTH
10 July 2019 - Following a nationwide call for nominations, CADTH is pleased to announce the membership of its new ...
Posted by Michael Wonder on 30 May 2019
Use of real world data sources for Canadian drug pricing and reimbursement decisions: stakeholder views and lessons for other countries
29 May 2019 - Canada has a long history of the use of clinical evidence to support health care decision making. ...
Posted by Michael Wonder on 25 Mar 2019
Canadian public places high priority on drugs’ safety, effectiveness, and certainty of evidence
25 March 2019 - Survey reveals top values for drug coverage decision making. ...
Posted by Michael Wonder on 06 Mar 2019
Patient advocacy groups in Canada with ties to pharma are big boosters for government coverage
5 March 2019 - As the interplay between the pharmaceutical industry and patient advocacy groups undergoes stepped-up scrutiny, a new ...
Posted by Michael Wonder on 05 Mar 2019
Evaluating Canadians’ values for drug coverage decision making
2 March 2019 - Decision makers are facing growing challenges in prioritising drugs for reimbursement because of soaring drug costs and ...
Posted by Michael Wonder on 21 Feb 2019
How big pharma donations may influence public drug coverage
21 February 2019 - A new review of 372 patient group submissions to the CADTH – about whether new medicines should ...
Posted by Michael Wonder on 10 Feb 2019
How procurement judges the value of medical technologies: a review of health care tenders
8 February 2019 - Procurement's important role in healthcare decision making has encouraged criticism and calls for greater collaboration with health ...